Asian Spectator

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

  • Written by ACN Newswire - Press Releases

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

SHANGHAI, CHINA, Jul 20, 2020 - (ACN Newswire) - Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, today announced that it has successfully closed US$97 million in Series C financing.

The...

More Articles ...

  1. Top 7 Benefits That a CBD-Rich Oil Can Potentially Offer
  2. Australians concerned about their financial wellbeing as a result of COVID-19
  3. Fivetran Raises $100 Million to Accelerate Growth as Automated Data Integration Leader
  4. Commodities Intelligence Centre (CIC) introduces international Trade Data and Business Services, partners SBF to drive digital transformation of Singapore SMEs

Magazine

Jokowi gagal kurangi konflik di Papua, bisakah kita berharap pada Prabowo?

Presiden Prabowo Subianto.Situs resmi Partai GerindraPrabowo-Gibran yang pencalonannya sebagai Presiden dan Wakil Presiden memantik kontroversi telah bekerja sejak 20 Oktober 2024.Untuk mengawal pemer...

Ada alasan mengapa para Zilenial kerap ‘ngeyel’ dan ogah menjadi manager di kantor

Research shows that over half of Gen Z have no interest in pursuing middle management roles, meaning they are missing out on valuable opportunities. (Shutterstock)Gen Z akan menjadi generasi populasi ...

Menuju COP 29: Menakar ambisi iklim pemerintahan Prabowo-Gibran

Prabowo-Gibran yang pencalonannya sebagai Presiden dan Wakil Presiden memantik kontroversi akan bekerja mulai 20 Oktober 2024.Untuk mengawal pemerintahan mereka, kami menerbitkan edisi khusus #PantauP...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion